Risankizumab for the Treatment of Plaque Psoriasis in Adults

Prescriber - United Kingdom
doi 10.1002/psb.1812
Full Text
Abstract

Available in full text

Categories
Pharmacology
Date
Authors
Publisher

Wiley

Related search

Risankizumab vs. Ustekinumab for Plaque Psoriasis

British Journal of Dermatology
DermatologyMedicine
2019English

Tildrakizumab for the Treatment of Plaque Psoriasis in Adults

Prescriber
Pharmacology
2019English

Risankizumab Versus Ustekinumab for Plaque Psoriasis: A Critical Appraisal

British Journal of Dermatology
DermatologyMedicine
2019English

Meta‐analyses of Clinical Efficacy of Risankizumab and Adalimumab in Chronic Plaque Psoriasis: Supporting Evidence of Risankizumab Superiority

Clinical Pharmacology and Therapeutics
Pharmacology
2019English

Infliximab for the Treatment of Plaque Psoriasis

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2008English

Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis

JAMA Dermatology
DermatologyMedicine
2020English

Dimethyl Fumarate for the Treatment of Plaque Psoriasis

Prescriber
Pharmacology
2018English

Monoclonal Antibodies for the Treatment of Plaque Psoriasis

Prescriber
Pharmacology
2019English

From the Medical Board of the National Psoriasis Foundation: Treatment Targets for Plaque Psoriasis

Journal of the American Academy of Dermatology
Dermatology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy